Stock Research: GSK

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

GSK

LSE:GSK GB00BN7SWP63
12
  • Value
    6
  • Growth
    29
  • Safety
    Safety
    82
  • Combined
    15
  • Sentiment
    44
  • 360° View
    360° View
    12
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

GSK plc is a global biopharma company focused on developing medicines and vaccines. It operates in the pharmaceuticals industry, with a focus on respiratory, immunology, oncology, HIV, and infectious diseases. GSK's operations are global. In the last fiscal year, the company had a market cap of $76,670 million, profits of $28,223 million, and revenue of $39,254 million, with 68629 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 12 (better than 12% compared with alternatives), overall professional sentiment and financial characteristics for the stock GSK are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for GSK. Only the consolidated Value Rank has an attractive rank of 82, which means that the share price of GSK is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 82% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 29, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 6, meaning the company has a riskier financing structure than 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 56% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 44. ...read more

more
Index
FTSE All Shares
FTSE 100
FTSE 350
Dividends Europe
Employee Focus EU
Diversity Europe
Human Rights
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
82 88 89 86
Growth
29 16 55 21
Safety
Safety
6 20 8 1
Sentiment
44 69 70 16
360° View
360° View
12 54 63 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
7 13 19 33
Opinions Change
80 81 71 16
Pro Holdings
n/a 87 80 78
Market Pulse
43 52 65 25
Sentiment
44 69 70 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
82 88 89 86
Growth
29 16 55 21
Safety Safety
6 20 8 1
Combined
15 38 46 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
88 91 89 87
Price vs. Earnings (P/E)
56 50 67 85
Price vs. Book (P/B)
15 20 26 34
Dividend Yield
90 96 96 92
Value
82 88 89 86
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
36 42 39 37
Profit Growth
38 38 58 23
Capital Growth
17 17 64 6
Stock Returns
81 32 52 78
Growth
29 16 55 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
10 13 6 7
Refinancing
3 11 9 1
Liquidity
49 71 45 41
Safety Safety
6 20 8 1

Similar Stocks

Discover high‑ranked alternatives to GSK and broaden your portfolio horizons.

Ipsen

ENXTPA:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

Schroders

LSE:SDR
Country: United Kingdom
Industry: Asset Management & Custody
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.